The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kaminnyi A.I.

Chazov National Medical Center of Cardiology

Shuvalova Yu.A.

Chazov National Medical Center of Cardiology

Kaminnaya V.I.

Chazov National Medical Center of Cardiology

Paleyev F.N.

Chazov National Medical Research Center of Cardiology

Inflammation in pathogenesis of cardiovascular diseases and prospects for targeted anti-inflammatory therapy

Authors:

Kaminnyi A.I., Shuvalova Yu.A., Kaminnaya V.I., Paleyev F.N.

More about the authors

Journal: Russian Cardiology Bulletin. 2025;20(4): 5‑9

DOI: 10.17116/Cardiobulletin2025200415

Read: 543 times

Download PDF (RU)
Contact the author
Table of contents

INFLAMMATION IN PATHOGENESIS OF CARDIOVASCULAR DISEASES AND PROSPECTS FOR TARGETED ANTI-INFLAMMATORY THERAPY
INFLAMMATION IN PATHOGENESIS OF CARDIOVASCULAR DISEASES AND PROSPECTS FOR TARGETED ANTI-INFLAMMATORY THERAPY

To cite this article:

Kaminnyi AI, Shuvalova YuA, Kaminnaya VI, Paleyev FN. Inflammation in pathogenesis of cardiovascular diseases and prospects for targeted anti-inflammatory therapy. Russian Cardiology Bulletin. 2025;20(4):5‑9. (In Russ.)
https://doi.org/10.17116/Cardiobulletin2025200415

Подписка 2026 Кардиологический вестник (Russian Cardiology Bulletin)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Therapeutic pote­ntial of quercetin and its deri­vatives against COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):44-50
Expe­rience with sele­ctive plasmosorption of cfDNA/NETs in a patient with severe acute pancreatitis (case report). Russian Journal of Anesthesiology and Reanimatology. 2025;(4):87-94
Effect of urolithin A on production of inte­rleukins 6 and 10 by immune cells from patients with MS and healthy donors. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):84-88
Esti­mation of pro-inflammatory cyto­kines and C-reactive protein levels in patients with acute demye­lination episode. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):118-121
Expe­rimental and clinical evaluation of the safety and effi­cacy of Poly­dexa spray with phenylephrine in acute rhinosinusitis. Russian Bulletin of Otorhinolaryngology. 2025;(4):39-46
The role of Inflasinusans in the treatment of acute rhinosinusitis. Russian Bulletin of Otorhinolaryngology. 2025;(4):64-71
Use of ozone therapy in the treatment of complications following pene­trating kera­toplasty for rosa­cea-associated kera­titis. Russian Annals of Ophthalmology. 2025;(4):66-72
Inte­rleukin-6 as a biochemical marker of inte­stinal anastomotic leakage. Piro­gov Russian Journal of Surgery. 2025;(9):87-93
Psychodermatological aspe­cts of psoriasis, current condition of problem. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):403-411
The use of grape poly­phenols in combination with magnetic therapy in patients with bronchial asthma who have suffered a new coro­navirus infe­ction. Problems of Balneology, Physiotherapy and Exercise Therapy. 2025;(4):14-19
Abstract:

Chronic inflammation is an independent risk factor of atherosclerosis and cardiovascular diseases (CVD). The initiator of this process is innate immune response through activation of pro-inflammatory cytokines — interleukin-1β (IL-1β) and interleukin-6 (IL-6). This review discusses current concepts of the role of inflammation in pathogenesis of atherosclerosis, focusing on IL-6 signaling pathways, its soluble receptor (sIL-6R) and glycoprotein 130 (gp130), as well as of C-reactive protein (CRP) as clinical biomarker of inflammation. Evidence on the role of inflammation obtained from various studies is reviewed. Special attention is paid to prospects of targeted anti-inflammatory therapy, including inhibition of IL-1β pathway, global inhibition of IL-6, and selective blocking of its trans-signaling pathway using soluble gp130 (sgp130). This would likely suppress pathological inflammation in atherosclerosis while preserving cytokine’s important protective functions and will become a key objective of future research.

Keywords:

Interleukin-6
soluble glycoprotein 130
inflammation
trans-signaling pathway
C-reactive protein

Authors:

Kaminnyi A.I.

Chazov National Medical Center of Cardiology

Shuvalova Yu.A.

Chazov National Medical Center of Cardiology

Kaminnaya V.I.

Chazov National Medical Center of Cardiology

Paleyev F.N.

Chazov National Medical Research Center of Cardiology

Received:

29.09.2025

Accepted:

19.10.2025

Close metadata

References:

  1. Ridker PM, Rane M. Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease. Circ Res. 2021 May 28;128(11):1728-1746. https://doi.org/10.1161/CIRCRESAHA.121.319077
  2. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2045-51.  https://doi.org/10.1161/ATVBAHA.108.179705
  3. Ridker PM. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection. Circ Res. 2016 Jan 8;118(1):145-56.  https://doi.org/10.1161/CIRCRESAHA.115.306656
  4. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ; CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017 Sep 21;377(12):1119-1131. https://doi.org/10.1056/NEJMoa1707914
  5. Ridker PM, Libby P, MacFadyen JG, Thuren T, Ballantyne C, Fonseca F, Koenig W, Shimokawa H, Everett BM, Glynn RJ. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J. 2018 Oct 7;39(38):3499-3507. https://doi.org/10.1093/eurheartj/ehy310
  6. Rose-John S, Jenkins BJ, Garbers C, Moll JM, Scheller J. Targeting IL-6 trans-signalling: past, present and future prospects. Nat Rev Immunol. 2023 Oct;23(10):666-681.  https://doi.org/10.1038/s41577-023-00856-y
  7. Kaptoge S, Seshasai SR, Gao P, Freitag DF, Butterworth AS, Borglykke A, Di Angelantonio E, Gudnason V, Rumley A, Lowe GD, Jørgensen T, Danesh J. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J. 2014 Mar;35(9):578-89.  https://doi.org/10.1093/eurheartj/eht367
  8. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008 Oct 30;359(18):1897-908.  https://doi.org/10.1056/NEJMoa0707402
  9. Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, Gorman DN, Gao P, Saleheen D. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012;379(9822):1205-1213. https://doi.org/10.1016/S0140-6736(11)61931-4
  10. Tanaka T., Narazaki M., Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10):a016295. https://doi.org/10.1101/cshperspect.a016295
  11. Serrano A.L., Baeza-Raja B., Perdiguero E., Jardi M., Munoz-Canoves P. Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy. Cell Metab. 2008;7(1):33-44.  https://doi.org/10.1016/j.cmet.2007.11.011
  12. Schmidt-Arras D, Rose-John S. IL-6 pathway in the liver: From physiopathology to therapy. J Hepatol. 2016;64(6):1403-1415. https://doi.org/10.1016/j.jhep.2016.02.004
  13. Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2012;8(8):457-465.  https://doi.org/10.1038/nrendo.2012.49
  14. Hirano T. IL-6 in inflammation, autoimmunity and cancer. Int Immunol. 2021;33(3):127-148.  https://doi.org/10.1093/intimm/dxaa078
  15. Rose-John S. The soluble interleukin-6 receptor and related proteins. Best Pract Res Clin Endocrinol Metab. 2015;29(5):787-797.  https://doi.org/10.1016/j.beem.2015.07.001
  16. Schuett H, Luchtefeld M, Grothusen C, Grote K, Schieffer B. How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb Haemost. 2009;102(2):215-222.  https://doi.org/10.1160/TH09-05-0297
  17. Ridker PM, Rane M. Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease. Circ Res. 2021;128(11):1728-1746. https://doi.org/10.1161/CIRCRESAHA.121.319077
  18. Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes. 2005 Dec;54 Suppl 2:S114-24.  https://doi.org/10.2337/diabetes.54.suppl_2.s114
  19. Kumari N, Dwarakanath BS, Das A., Bhatt AN. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 2016;37(9): 11553-11572. https://doi.org/10.1007/s13277-016-5098-7
  20. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011 May;1813(5):878-88.  https://doi.org/10.1016/j.bbamcr.2011.01.034
  21. Schuett H, Oestreich R, Waetzig GH, Annema W, Luchtefeld M, Hillmer A, Bavendiek U, von Felden J, Divchev D, Kempf T, Wollert KC, Seegert D, Rose-John S, Tietge UJ, Schieffer B, Grote K. Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2012 Feb;32(2):281-90.  https://doi.org/10.1161/ATVBAHA.111.229435
  22. Ridker PM, Devalaraja M, Baeres FMM, Engelmann MDM, Hovingh GK, Ivkovic M, Lo L, Kling D, Pergola P, Raj D, Libby P, Davidson M; RESCUE Investigators. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021 May 29;397(10289):2060-2069. https://doi.org/10.1016/S0140-6736(21)00520-1
  23. Garbers C, Hermanns HM, Schaper F, Müller-Newen G, Grötzinger J, Rose-John S, Scheller J. Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev. 2012 Jun;23(3):85-97.  https://doi.org/10.1016/j.cytogfr.2012.04.001
  24. Jostock T, Müllberg J, Ozbek S, Atreya R, Blinn G, Voltz N, Fischer M, Neurath MF, Rose-John S. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem. 2001 Jan;268(1):160-7.  https://doi.org/10.1046/j.1432-1327.2001.01867.x
  25. Rabe B, Chalaris A, May U, Waetzig GH, Seegert D, Williams AS, Jones SA, Rose-John S, Scheller J. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood. 2008 Feb 1;111(3):1021-8.  https://doi.org/10.1182/blood-2007-07-102137
  26. Barkhausen T, Tschernig T, Rosenstiel P, van Griensven M, Vonberg RP, Dorsch M, Mueller-Heine A, Chalaris A, Scheller J, Rose-John S, Seegert D, Krettek C, Waetzig GH. Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model. Crit Care Med. 2011 Jun;39(6):1407-13.  https://doi.org/10.1097/CCM.0b013e318211ff56
  27. Swerdlow DI, Holmes MV, Kuchenbaecker KB, Engmann JE, Shah T, Sofat R, Guo Y, Chung C, Peasey A, Pfister R, Mooijaart SP, Ireland HA, Leusink M. The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis. Lancet. 2012 Mar 31;379(9822):1214-24.  https://doi.org/10.1016/S0140-6736(12)60110-X
  28. Cai T, Zhang Y, Ho YL, Link N, Sun J, Huang J, Cai TA, Damrauer S, Ahuja Y, Honerlaw J, Huang J, Costa L, Schubert P, Hong C, Gagnon D, Sun YV, Gaziano JM, Wilson P, Cho K, Tsao P, O’Donnell CJ, Liao KP; VA Million Veteran Program. Association of Interleukin 6 Receptor Variant With Cardiovascular Disease Effects of Interleukin 6 Receptor Blocking Therapy: A Phenome-Wide Association Study. JAMA Cardiol. 2018 Sep 1;3(9):849-857.  https://doi.org/10.1001/jamacardio.2018.2287
  29. Schreiber S, Aden K, Bernardes JP, Conrad C, Tran F, Höper H, Volk V, Mishra N, Blase JI, Nikolaus S, Bethge J, Kühbacher T, Röcken C, Chen M, Cottingham I, Petri N, Rasmussen BB, Lokau J, Lenk L, Garbers C, Feuerhake F, Rose-John S, Waetzig GH, Rosenstiel P. Therapeutic Interleukin-6 Trans-signaling Inhibition by Olamkicept (sgp130Fc) in Patients With Active Inflammatory Bowel Disease. Gastroenterology. 2021 Jun;160(7):2354-2366.e11.  https://doi.org/10.1053/j.gastro.2021.02.062
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.